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Previous studies in this laboratory (1)  and  elsewhere (2)  have established 
that neutralizing antibodies for the infecting strain of poliomyelitis virus are 
as a rule demonstrable in patients at, or shortly after, onset of first symptoms 
and continue to increase in titer during convalescence. Further studies on the 
same patients have indicated that the high titers of homologous antibody which 
were found at 3 months were still present at 3 years after onset (3). The recent 
~,ork on immunologic classification of the poliomyelitis viruses, which  indi- 
cated the existence of 3 distinct types, did not reveal a common antigen among 
them (4).  Similarly, recently reported observations on complement-fixing (CF) 
antigens derived from the  different types of poliomyelitis virus,  yielded no 
evidence of a common antigen when sera from hyperimmunized or from intra- 
cerebrally  inoculated  convalescent  monkeys were  used  for  the  tests  (5-8). 
Evidence  for  the  existence  of  group-specific  CF  antibodies  was,  however, 
obtained in studies on patients. Persons, proved to be infected with Type 1 
(Brunhilde-like) poliomyelitis virus, who exhibited no evidence of past or con- 
current  infection with Type  2  (Lansing-like)  virus,  nevertheless,  either de- 
veloped Type 2, CF antibody in increasing titer, or, very shortly after onset of 
first symptoms, were found to possess such antibody in titers of a magnitude 
only rarely encountered in healthy individuals tested  as  controls  (9).  This 
heterotypic CF antibody response completely disappeared in a few patients 3 
months after onset, and in 50 per cent of the patients the titers exhibited a 
fourfold or greater drop by 3 months (9). During the course of this latter study 
(9) it was observed that a patient, who was proved to have been infected with 
a  Type 1 poliomyelitis virus,  had Type 2 neutralizing antibody, 3 days after 
onset, which completely disappeared between 2 and 4 weeks after onset. This 
observation led to the study, to be reported here, in which the Type 2 neutral- 
izing antibody response  was  determined at various times during the  first 3 
months after onset of poliomeylitis in  18 patients from whom Type  1 virus 
was recovered. 
* Aided by a grant from The National Foundation for Infantile Paralysis, Inc. 
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Materials and Methods 
Patients Studied.--The  18 patients are part of a  group described in a  previous communi- 
cation  (1). 9  had the paralytic disease and 9  were diagnosed as having non-paralytic polio- 
myelitis. All had  their illness in  1947;  8  were derived from an epidemic in  Cincinnati,  and 
TABLE  I 
Type 2 Neutralizing Antibody  in Poliomyelitis Patients from  Whom Type 1 Virus  Was Recovered 
i 
type 2 !  Time  Type I 
leutra-  Test  for  Patient  after  Type 2  neutralizing  Type 2, CF antibody  neutralizing 
onset  antibody  antibody  lizlng  Type 2  Age  Ist 
anti-  neutralizing  seruin  )ody in  antibody 
acute  ob-  phase  No.  Name  Ill-  Ist  2  4  3  ist  2  4  3  Ist  3 
ness*  rained serum  wks. wks.  mos. ;erum  wks. wks. ~aos  serum  mos. 
yrs.  days 
Serum  di-  1  Sic.  NP  15  I  1:6  1:32 1:62  1:38  96  64 
Posi-  lutions  2  Col.  NP  12  1  1:16  1:64 1:85  1:32  12  32 
tive  ~$. 50  3  Pet.  NP  13  2  1:3  1:8  1:25  1:17  16  128 
LD~o of  4  Hopk.  P  2  2  1:12  1:24 1:36  1:11  8  24 
virus  5  Kau.  P  11  3  1:32:~  1:2  0  0  128  128 
1:20  <1:2  0  0 
6  Fro.  P  6/12  3  1:40  --  --  1:16  --  2  2 
1:2 
~ega- 
tire 
Undiluted  7 
serum ~$.  8 
various  9 
dilutions  10 
of virus  11 
12 
13 
14 
i  15 
16 
17 
[  IS 
i 
Fin.  P  ~  I  13--  32  50  6--  <2  4  4¶ 
Obe.  P  13  1  5--  1000  250  3--  2  12  8 
Kni.  NP  2  1  10--  30  16-- 20--  192  128  96 
Yea.  NP  0.3  6  10  50  200  4  8  4 
Wal.  NP  2  2  5--  50  -- 
Ris.  P  18/12  3  13--  63  32  4--  --  8  4¶ 
Fal.  NP  3~  3  6--  20  10  10--  16  32  32 
Hopp.  P  18/12  4  5--  25  5---  5--  6  12  8 
Hof.  1VP  4  3  6--  16--  10--  5--  --  <~2 
Vau.  NP  8  5  6--  13--  6---  100-I-~  16  8  12 
Ric.  P  6/12  5  5--  20-- 16---  160+$~ 
Ten.  P  7  2  25  20  10  800~:~ 
64  32  --  -- 
32  32  --  -- 
64  24  --  -- 
24  4  1:32  1:214-{- 
96  64  1:32  1:128 
--  1:2?  1:6U 
1:128 
--  1:12  1:194+ 
4  1:2  1:64 
48  -- 
16"*  1600"* 
--  1:6  1:26 
32  --  -- 
6  --  -- 
--.  --  10--*'  ~** 
48  -- 
1:32  1:214+ 
1:2  1:52 
* NP =  non-paralytlc; P  =  paralytic. 
The results of the first test are shown in the numerator, and those of the second test in the denominator. 
§The first test in 1948 yielded a titer of 1:16 and on repetition in 1951 the tlter was 1:2; a test performed shnultano- 
ously on the 3-year specimen of this patient yielded a negative result. 
U  The higher titer in the denominator represents the result of a repeat test on this serum after storage for 3 years in 
frozen state. 
¶ The CF tests were negative on the serum obtained 3 years after onset. 
** The values represent the neutralization index of undiluted serum. 
~:~ The 50 per cent serum dilution titer vs. 50 LD~0 of Type 2 virus was: 1:16 for Van. I: 200 for Ric.; also I: 200, 3 ye~m 
after onset. 1:4 for Ten.; 1:2, 3 years after onset. 
1O from an epidemic in Akron. The 18 strains of poliomyelitis virus recovered from the ali- 
mentary  tract of these patients were all subsequently  (4) classified  as Type  I. Ii of these 
patients  were also included in a subsequent  study with Type  2 poliomyelitis  CF  antigen 
(9), and 7 of them were also investigated  for persistence  of neutralizing  antibody against 
their own strain of virus 3 years after onset (3). 
Serum Specimens.--The  specimens were all collected in 1947 (I) and stored in the frozen 
state in a chest containing solid COz. Acute phase specimens were obtained between 8 hours 
and 5 days after onset (Table 1), and the others at 2 weeks, 4 weeks, and 3 months after 
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Tests  for Type 2 Neutralizing Antibody.--Qualitative and quantitative tests were performed 
in mice using aliquots of a frozen preparation of the Lansing strain of virus. In the qualita- 
tive tests the mixtures consisted of undiluted serum and 3 fivefold or tenfold serial dilutions 
of virus, incubated at room  temperature for  1 hour prior to inoculation into groups of 8 
mice. A control titration of the virus in 0.9 per cent solution of NaC1 accompanied each test, 
but the neutralization index was calculated on the basis of a cumulative LDs0 derived from 
multiple control titratious using 8 to 20 mice per dilution. The neutralization index is the con- 
trol LDt0 titer divided by the LD~0 titer of the virus in the presence of serum, and  a  value 
of 50 or over was regarded as indicating the presence of antibody. Neutralization indexes of 
less than 30 were regarded as negative and those between 30 and 50, as questionable. In 
the quantitative tests the mixtures consisted of  serial fourfold dilutions of serum and 50 
LDt0 of virus per 0.03 ml. of mixture, the result being expressed as the final dilution of serum 
capable of protecting 50 per cent of  the mice; the  50 per cent end-point was calculated by 
the method of Reed and Muench. 
In both the qualitative and quantitative  tests  the mice were observed for 35 days. This 
was done because repeated observations on control titrations with 20 to 140 mice per dilution 
of virus on at least 4  different pools of  the Lansing virus (about 200 mouse passages)  re- 
vealed that the LDs0 titer at 35 days was consistently from 0.3 to 0.6 of a  log higher than 
at 21 days. The longer period of observation may result in somewhat lower values for neu- 
tralizing antibody in both the qualitative and quantitative tests because the proportion Of 
mice exhibiting incubation periods of 21 to 35 days is much higher among those inoculated 
with antibody-virus mixtures than among controls. An examination of the protocols revealed 
that sera regarded as negative on the 35 day basis did not become positive on the 21 day 
basis. However,  sera with neutralization indexes between 30 and 50 on the 35  day basis 
occasionally yielded indexes of 50 on the 21 day basis. Thus, the 2 week serum of patient Fin., 
recorded as having a  neutralization index of 32 on the 35 day basis (Table I), revealed an 
index of 63 on the 21 day basis. 
In the quantitative test all 4 sera of one patient were examined in a single test, because 
when that is done, fourfold or greater differences in titer can be regarded as representing real 
differences in concentration of antibody. This reproducibility of the 50 per cent neutraliza- 
tion end-point of a  serum has been found not only in duplicate tests in this laboratory em- 
ploying fourfold dilutions of serum, but also by Bell (10) with tenfold dilutions of serum. 
Tests for Type 1 Neutralizing Antibody.--The  results of simultaneous quantitative tests 
in monkeys on the acute phase and 3 month convalescent sera using the patient's own virus 
have already been reported for 9 of the 10 patients (1), and are reproduced in Table I. The 
titers in Table I  are double those in the original report (1), because the final serum dilutions 
are given here in conformity with those recorded for the Type 2 neutralizing antibody. The 
tests onsthe 3 month sera of 7 of the patients were repeated 3 years later as part of another 
study (3), and were found to be as high or higher than those recorded in Table I. The acute 
phase and 3 month sera of patient Kan. were examined in a  single test during the present 
study, using a  Type 1 virus derived from another patient, Obe., in the same epidemic, be- 
cause the virus recovered from Kan. was of insufficient potency for quantitative neutraliza- 
tion tests in monkeys.  1 Mixtures consisting of serial, fourfold dilutions of serum and  100 
PD602 of virus were inoculated into groups of 4 rhesus monkeys, and the 50 per cent serum 
dilution end-point determined by the method of Reed and Muench. 
Tests/or Type 2, CF Antibody.--The  CF tests were performed by Dr. Jordi Casals at the 
Laboratories of the Rockefeller Institute, and are recorded in Table I  to provide a complete 
11 am indebted to Dr. Johan Winsser for assistance in the performance of this test. 
g PDs0 means 50 per cent poliomyelitis dose because the calculation takes into account 
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antibody spectrum on this series of patients. The data on 11 of these patients appear in the 
report by Casals, Olitsky, and Sahin (9). The data on patients Fro., Fin., Ris., and Hof. were 
not previously recorded because they were carried out with CF antigens of lower titer, but 
not less than 4 units.* 
RESULTS 
The  data  on  the  18  patients  investigated in  this  study are  presented  in 
Table I. Although Type 1 poliomyelitis  virus was recovered from the alimentary 
tract of all these patients and it is highly probable that it was responsible for 
the current illness,  diagnosed as paralytic or non-paralytic poliomyelitis, one 
can be certain of this only in the 10 patients whose sera were also tested for 
homotypic neutralizing antibody. 
Patients with Type 2 Neutralizing Antibody during Acute Phase.--6 of the 18 
patients had Type 2 neutralizing antibody in the acute phase serum specimens, 
obtained 1 to 3 days after onset; the titers in these sera ranged from 1:3 to 
1:40, and during subsequent weeks the level of this antibody exhibited a some- 
what different pattern in each of these patients. In 3 of them (Sic.,  Col., and 
Pet.) the titer increased fivefold to tenfold between 1 to 2 days and 4 weeks 
after onset; while there was a  downward trend thereafter, the titers in the 3 
month sera were still 2 to 6 times higher than in the acute phase specimens. 
Bell (10)  performed quantitative tests for Lansing antibody on serial serum 
specimens obtained from 4 normal individuals over a period of 3 to 10 months, 
and the maximum variation in titer was 0.3 of a log, i.e. no more than a  two- 
fold difference, which probably represents the limits of accuracy of the test. 
The changes in titer which exceed this twofold range may, therefore, be re- 
garded as representing a  variation in antibody concentration that does not 
ordinarily occur without antigenic stimulation. In these 3 patients one cannot 
rule out a concurrent infection with a Type 2 poliomyelitis virus, and the results 
of the Type 2, CF tests do not help in reaching a decision because similar pat- 
terns are found in patients without Type 2 neutralizing antibody. However, 
in view of the results obtained in  the  other  patients,  a  concurrent  infection 
with Type 2 virus is not necessarily the real cause of the observed events. In 
patient Hopk.  the Type 2 neutralizing antibody is present in the saflae titer 
in the 2 day and 3 month specimens, while the 2 week and 4 week specimens 
show  twofold and  threefold  greater  titers  respectively.  Although  one  may 
question  the  significance of this  twofold and  threefold difference, the  same 
fluctuation is apparent  in the Type 2,  CF antibody titers.  In contrast with 
these data for the T3rpe 2 virus, patient Hopk.  exhibits a  sevenfold greater 
titer of homotypic neutralizing antibody in the 3  month than in the  2  day 
serum specimen. The data on patient Kau. are of special significance, because 
they show that a person proved to have been infected with Type 1 poliomyelitis 
* I  am indebted to Dr. Jordi Casals for permission to insert these results in the present. 
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virus,  by both virus recovery and development of increasing  and persistent 
titer of homotypic antibody, can have Type 2 neutralizing antibody in a titer 
of 1:32 at 3 days after onset which completely disappears  within 2 to 4 weeks 
after onset; the 4  sera  were tested twice  with almost identical results.  The 
only plausible interpretation of the whole pattern of the results on this patient 
is that infection with a Type 1 poliomyelitis virus stimulated a rapid production 
of both neutralizing and CF antibodies for Type 2 virus, the former persisting 
for only about 2 weeks and the latter for 3 months or longer. The same inter- 
pretation is probably valid for the data obtained on Fro., but because  this 
patient was only 6 months old at onset it is also necessary to consider the pos- 
sibility  of  unusually long  persistence  of placentally transmitted  antibody. 
Against this possibility  are the rather high titer of 1:40 at 6 months of age 
and the presence of antibody at 9 months of age. It is clear, however, that the 
Type 2 neutralizing antibody did not persist,  since it was completely absent 
3 years later when the homotypic neutralizing antibody was still present in 
high titer (3). 
Patients without Type 2 Neutralizing Antibody during Acute Phase.--Six  of 
the 12 patients in this group developed Type 2 neutralizing antibody (neutrali- 
zation indexes of 50 to 1,000) between  0.3 to 3 days and 2 to 4 weeks after 
onset.  In only 1 of these 6 was this antibody still present at 3 months. The 
Type 2, CF antibody, tested serially in 4 of these 6 patients, rose fourfold to 
sixfold during the first 2 weeks in 2 patients. 4 of this group of 6 patients were 
unquestionably infected with the Type 1 virus recovered from them during the 
acute phase  of their illness, because  they developed homotypic neutralizing 
antibody in increasing titer demonstrable not only at 3 months but also at 3 
years in the 3 who were tested at that time (3). In the remaining 6 patients of 
this group, there was no significant development of Type 2 neutralizing anti- 
body during the first 4 weeks after onset. 3 of them, however, developed Type 
2 neutralizing antibody between 4 weeks and 3 months after onset  of their 
clinically diagnosed illness as previously reported (1). In one of these 3 patients 
there was a fourfold increase in Type 2, CF antibody during the same period, 
and in the other 2 patients the newly developed Type 2 neutralizing  antibody 
was still  present in undiminished titer 3 years later (3);  the most plausible 
interpretation of these data, in the light of the rapid and transitory appearance 
of the heterotypic antibody in the other patients is that these 3 patients were 
infected with Type 2 poliomyelitis virus, 4 weeks or more after onset of their 
clinically apparent infection with Type 1 virus. 
The data on this group of 12 patients indicate that a certain proportion (in 
this case, 50 per cent) of patients, who are infected with Type 1 virus,  can 
develop  Type 2 neutralizing antibody during the first 4  weeks after onset, 
which in most instances  is no longer detectable at 3 months after onset. The 
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amount of Type 2 neutralizing antibody. The Type 2,  CF antibody generally 
appeared earlier and persisted longer than the Type 2 neutralizing antibody. 
DISCUSSION 
The results of the present study indicate that more than 50 per cent of pa- 
tients, infected with Type 1 poliomyelitis virus, develop Type 2 neutralizing 
antibodies within 2 to 4 weeks after onset, which in most instances disappear 
within 3 months. This rapid disappearance of neutralizing antibody stimulated 
by infection with heterotypic strains of poliomyelitis virus is to be contrasted 
with  the  long  persistence  of  the  homotypic  neutralizing  antibodies.  These 
data provide evidence for the  existence of a  common antigen  between  the 
Type 1 and Type 2 poliomyelitis viruses. They also provide a  reasonable ex- 
planation for certain observations of others which were previously difficult to 
understand. 
A number of investigators have reported patients whose sera neutralized Lansing 
virus during the first 2 to 4 weeks after onset but not later on. Turner and Young 
(ll) mentioned 5 patients (of 64 tested) whose sera neutralized Lansing virus 8 to 
17 days after onset but not 3 months later. Brown and Francis (12) reported that 
17 of 39 patients who had  Lansing neutralizing antibody during the acute phase 
(usually within 9 days after onset)  showed a decrease  (disappearance?)  during con- 
valescence (6 weeks to 1 year, usually 6 months, after onset); among 18 contacts of 
patients, who had antibody in the first serum specimen, there were 10 whose serum 
failed to neutralize the virus 1 year later. BothTurner  and Young (11) and Brown and 
Francis (12) used 100 or more LD60 of virus in their tests and both the positive and 
negative results have a greater validity than similar observations of others (13, 14) 
obtained with approximately 10 LDso of virus.  Clark and Rhodes (15) recently re- 
ported that 4 of 6 Eskimo patients who had Lansing antibody at 3 to 4 weeks after 
onset of poliomyelitis  failed to neutralize the virus at 12 months, and that another 
Eskimo patient with antibody 6 days after onset had none at 9 weeks. Although the 
available evidence indicated that the Eskimo epidemic was caused by non-Lansing 
strains  of virus,  these  investigators  (15) were  inclined  to interpret  their data  as 
indicating that Lansing antibody persists  for only a short time after primary infec- 
tion and that repeated infections are necessary to produce a more persistent immune 
response. 
From the data reported in the present communication, it is clear that the 
transitory appearance of Lansing antibody reported by the previous investi- 
gators (11-15) is most likely the result of infection with Type 1 or other non- 
Lansing types of poliomyelitis virus. 
It is also clear from the data presented here that the appearance of Lansing 
antibody during the first 4 weeks after onset in patients who had none during 
the first few days of their illness, as was reported for 9 of 23 patients by Ham- 
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were infected with Lansing-like strains of virus. Similarly, serologic surveys for 
Lansing antibody carried out on normal children shortly before and after the 
summer and autumn months (17) may be expected to yield results  which re- 
flect the incidence of inapparent infection not only with Type 2 strains but, to 
a lesser extent, also with Type 1 or other non-Lansing types of poliomyelitis 
virus. The data presented in this communication emphasize the fact  that it 
will be necessary to study the antibody response of patients to all 3 types of 
poliomyelitis virus, before a  proper basis can be established for the serologic 
diagnosis of the immunologic type of poliomyelitis virus responsible for human 
infections. 
S~Y  AND  CONCLUSIONS 
Neutralizing antibodies for Type 2 (Lansing) poliomyelitis virus were tested 
periodically in a  group of 18 patients from whom Type 1 poliomyelitis virus 
was recovered. Data for homotypic neutralizing antibodies and Type 2 com- 
plement-fixing antibodies were also available on the majority of these patients. 
The results indicated that Type 2  neutralizing antibodies first appeared  or 
significantly increased in titer in 11 of the 18 patients during the first 2 to 4 
weeks after onset. In most patients the Type 2 neutralizing antibody either 
completely disappeared at 3 months (in one patient between 2 and 4 weeks) 
or dropped in titer, while the Type 1 or homotypic antibody persisted in high 
titer. These results are interpreted as indicating that the Type 1 and Type 2 
poliomyelitis viruses share a  common antigen, and that the heterotypic anti- 
body response is transitory while the homotypic neutralizing antibody persists 
for  a  longer  time. 
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